Tags Bharat Biotech
Tag: Bharat Biotech
Experts have speculated that the Delta Plus variant may be responsible for the third wave of COVID-19.
EUL is necessary for vaccine companies to supply their vaccines for international procurement.
WHO Chief Scientist Dr. Soumya Swaminathan said that the data of Covaxin trial "looks good".
Covaxin has been found to be 65% effective against the delta variant of the COVID-19.
Covaxin has been found to be 77.8% effective in the third phase trial.
Bharat Biotech had released interim data for Phase III trials in March.
Bharat Biotech's COVID-19 vaccine 'Covaxin' may get approval from the WHO soon.
AIIMS Delhi will next conduct trials on 2-6 years age group children after this trial.
AIIMS Delhi will study the effect of the vaccine on children and the body's immunity.
Bharat Biotech will now conduct trial of the vaccine in 525 healthy volunteers.